XNASNEO
Market cap1.90bUSD
Jan 10, Last price
14.77USD
1D
-20.63%
1Q
9.16%
Jan 2017
72.35%
IPO
392.33%
Name
Neogenomics Inc
Chart & Performance
Profile
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 591,643 16.07% | 509,728 5.24% | |||||||
Cost of revenue | 688,291 | 662,835 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (96,648) | (153,107) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (9,129) | (15,092) | |||||||
Tax Rate | |||||||||
NOPAT | (87,519) | (138,015) | |||||||
Net income | (87,968) -39.02% | (144,250) 1,628.17% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 4,624 | 12,587 | |||||||
BB yield | -0.23% | -1.10% | |||||||
Debt | |||||||||
Debt current | 11,220 | 6,654 | |||||||
Long-term debt | 679,550 | 679,880 | |||||||
Deferred revenue | 19 | ||||||||
Other long-term liabilities | 13,034 | 13,036 | |||||||
Net debt | 275,567 | 248,514 | |||||||
Cash flow | |||||||||
Cash from operating activities | (1,953) | (65,993) | |||||||
CAPEX | (28,752) | (30,891) | |||||||
Cash from investing activities | 76,707 | 517 | |||||||
Cash from financing activities | 4,554 | 11,829 | |||||||
FCF | (100,430) | (129,247) | |||||||
Balance | |||||||||
Cash | 415,203 | 437,989 | |||||||
Long term investments | 31 | ||||||||
Excess cash | 385,621 | 412,534 | |||||||
Stockholders' equity | (248,602) | (162,859) | |||||||
Invested Capital | 1,820,462 | 1,784,865 | |||||||
ROIC | |||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 125,502 | 124,217 | |||||||
Price | 16.18 75.11% | 9.24 -72.92% | |||||||
Market cap | 2,030,622 76.92% | 1,147,765 -71.96% | |||||||
EV | 2,306,189 | 1,396,279 | |||||||
EBITDA | (24,065) | (83,677) | |||||||
EV/EBITDA | |||||||||
Interest | 6,907 | 1,506 | |||||||
Interest/NOPBT |